Abstract: The cream formulation of the present invention is a topical cream made with antimycotic (amphotericin B) and a mixture of excipients where the water present in the formulation smoothes inflamed tissue. The cream has a particular application for the treatment of cutaneous leishmaniasis and mucosal leishmaniasis in humans and animals. The topical application avoids the risks of toxicity and the gastrointestinal hassles of pills treatments. It has greater acceptability from patient and does not require of valuations before, during or after treatment to check toxicity levels of the liver, kidney and heart.

Abstract: SAPONINS AND CHROMANS DERIVATIVES MIXTURE COMPOSITIONS AGAINST LEISHMANIASIS, TRYPANOSOMIASIS AMERICANA, MALARIA, TRYPANOSOMIASIS AFRICANA AND FASCIOLA HEPATICA, is a composition of saponins and chromans derivatives. The saponins are triterpene types and chromans are hydrazones derivatives. This composition is a therapeutic agent against tropical diseases.

Abstract: The use of quaternary halogenated ammonium salts for treating leishmaniasis infections and other parasitic diseases is described. Although there have been previous reports in which quaternary ammonium salts are used as antimalarial, antifungal, and antileishmanial compounds, the use of such salts containing a halogenated N-methyl substituent as a therapeutic agent against leishmaniasis had not been reported. The compounds described here, in specific those with a terminal arylalkenyl or diarylalkenyl moiety, are shown to inhibit the growth of Leishmania panamensis parasites, a known causative agent of leishmaniasis disease. In addition, the series of compounds are also extensive against malaria, Chagas disease, toxoplasmosis, and other parasitic diseases.

Abstract: The use of quaternary halogenated ammonium salts for treating leishmaniasis infections and other parasitic diseases is described. Although there have been previous reports in which quaternary ammonium salts are used as antimalarial, antifungal, and antileishmanial compounds, the use of such salts containing a halogenated N-methyl substituent as a therapeutic agent against leishmaniasis had not been reported. The compounds described here, in specific those with a terminal arylalkenyl or diarylalkenyl moiety, are shown to inhibit the growth of Leishmania panamensis parasites, a known causative agent of leishmaniasis disease. In addition, the series of compounds are also extensive against malaria, Chagas disease, toxoplasmosis, and other parasitic diseases.